Cover Image
市場調查報告書

Triptans(偏頭痛治療藥):市場預測與分析

Triptans (Migraine) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 301146
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
Triptans(偏頭痛治療藥):市場預測與分析 Triptans (Migraine) - Forecast and Market Analysis to 2023
出版日期: 2014年03月31日 內容資訊: 英文 63 Pages
簡介

Triptans是在偏頭痛發作時緊急治療用的藥劑。此外也用在畏光、畏聲和噁心等症狀上。Triptans是血清素(5-HT)受體的選擇性受體激動劑,對5-HT1級的受體(特別是5-HT1B·5-HT1D受體和部分5-HT1F受體)具有高度親和性。具有和不同種類受體不同的作用機制,5-HT1B可使腦內血管和心臟產生血管收縮,同時5-HT1D亦可對中軸神經系統神經原和三叉神經末端起作用。

本報告提供偏頭痛的治療藥之一──Triptans的全球市場相關分析,提供疾病概要和治療方法,競爭的企業·藥品概要,市場競爭概況,Triptans的商品資訊(特色·功效·安全性等),全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 本報告概要
  • 相關調查
  • 近日出版的相關調查

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預測
  • 症狀
    • 前驅症狀階段
    • 前兆階段
    • 疼痛的階段
    • 後發症狀的階段

第4章 疾病管理

  • 治療方法概要
    • 急性偏頭痛的治療
    • 偏頭痛的預防療法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估

第6章 關於Triptans

  • 概要
  • SWOT分析
  • Imitrex(sumatriptan)
    • 概要
    • 功效
    • 安全性
    • 未來預測
  • Zomig(zorumitoriputan)
  • Amerge(naratriptan)
  • Maxalt(Rizatriptan)
  • Axert(arumotoriputan)
  • Frova(furobatoriputan)
  • Relpax(eletriptan)

第7章 附錄

圖表一覽

目錄
Product Code: GDHC371DFR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Triptans are indicated for the acute treatment of a migraine attack once it has begun, as well as its associated symptoms such as photophobia, phonophobia and nausea. Triptans are selective serotonin (5-HT) receptor agonists that display high affinity for the 5-HT1 class of receptors. Specifically these are the 5-HT1B and 5-HT1D receptor subtypes, as well as some having varying affinity for the 5-HT1F receptor subtype. Each of the individual subtypes has a different mechanism of action. The 5-HT1B subtype causes vasoconstriction in the cranial circulation and in the heart, whereas 5-HT1D subtypes are located on CNS neurons and trigeminal nerve endings.

Scope

  • Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Triptans including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Beta blockers for the top seven countries from 2012 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Triptans performance
  • Obtain sales forecast for Beta blockers from 2012-2023 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Triptans

  • 6.1. Overview
  • 6.2. SWOT Analysis
  • 6.3. Imitrex (sumatriptan)
    • 6.3.1. Overview
    • 6.3.2. Efficacy
    • 6.3.3. Safety
    • 6.3.4. Forecast
  • 6.4. Zomig (zolmitriptan)
    • 6.4.1. Overview
    • 6.4.2. Efficacy
    • 6.4.3. Safety
    • 6.4.4. Forecast
  • 6.5. Amerge (naratriptan)
    • 6.5.1. Overview
    • 6.5.2. Efficacy
    • 6.5.3. Safety
    • 6.5.4. Forecast
  • 6.6. Maxalt (rizatriptan)
    • 6.6.1. Overview
    • 6.6.2. Efficacy
    • 6.6.3. Safety
    • 6.6.4. Forecast
  • 6.7. Axert (almotriptan)
    • 6.7.1. Overview
    • 6.7.2. Efficacy
    • 6.7.3. Safety
    • 6.7.4. Forecast
  • 6.8. Frova (frovatriptan)
    • 6.8.1. Overview
    • 6.8.2. Efficacy
    • 6.8.3. Safety
    • 6.8.4. Forecast
  • 6.9. Relpax (eletriptan)
    • 6.9.1. Overview
    • 6.9.2. Efficacy
    • 6.9.3. Safety
    • 6.9.4. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Migraine Patients
    • 7.4.2. Percent Drug-treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. Survey of Prescribing Physicians
  • 7.7. About the Authors
    • 7.7.1. Author
    • 7.7.2. Reviewer
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Product Profile - Triptans
  • Table 7: Triptans SWOT Analysis, 2013
  • Table 8: Global Sales Forecasts ($m) for Imitrex, 2012-2023
  • Table 9: Global Sales Forecasts ($m) for Zomig, 2012-2023
  • Table 10: Global Sales Forecasts ($m) for Amerge, 2012-2023
  • Table 11: Global Sales Forecasts ($m) for Maxalt, 2012-2023
  • Table 12: Global Sales Forecasts ($m) for Axert, 2012-2023
  • Table 13: Global Sales Forecasts ($m) for Frova, 2012-2023
  • Table 14: Global Sales Forecasts ($m) for Relpax, 2012-2023
  • Table 15: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
Back to Top